CD4+ Th1 HER2-Specific T Cells as a Novel Treatment for HER2-Overexpressing Breast Cancer

During the last research period, we have made significant progress in the development of our mouse neu-reactive T cell lines. First, we have confirmed the key CD4+ neu peptides (p101 and p373) most effective at priming T cell responses. Of the peptide-specific T cell lines tested, only p101- and p37...

Ausführliche Beschreibung